The year's most popular stories

Share this article:
The year's most popular stories
The year's most popular stories

There are lots of ways to write the kind of story that ends up on a list like this. You could take a deep dive sharing exclusive projections for industry marketing spend. You can seriously examine the aggressive pricing for oncology drugs in the US. Or you can pen a commentary about Angelina Jolie's views on holistic treatment.

MM&M's year-end list also captures approval and pipeline analysis (Eliquis, Sovaldi, Lemtrada), insights into what doctors need—as opposed to what pharma thinks they want—and a look at medical advertising's best DTC ads ever. Here are the 10 that sparked heaviest reader interest in 2013:

1. Angelina Jolie's flawed message

2. Healthcare Marketers Trend Report: The Big Shift

3. Will Kadcyla suffer the same fate as Zaltrap?

4. Year-end approval clears Eliquis for launch

5. Docs to pharma marketers: you're not getting it

6. Merck buys controlling stake in Physicians Interactive

7. Lemtrada's future in doubt after reviewers flag safety issues

8. MM&M's Best DTC Ads Ever

9. Is the current agency model a joke?

10. The Pipeline Report 2014: Class Seekers

Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.